Fig 1 - uploaded by Ashutosh Kumar
Content may be subject to copyright.
Effect of sulforaphane on nerve functions motor nerve conduction velocity (MNCV) and nerve blood flow (NBF) in diabetic rats. Effect of sulforaphane on nerve functions, MNCV and NBF, in treated diabetic animals was measured in sciatic-posterior tibial conducting system using Power Lab 8sp system and LASER Doppler system respectively. Sulforaphane treatment resulted in a significant reversal of nerve conduction and perfusion deficits suggesting its beneficial effects in diabetic neuropathy. ND: non diabetic; STZ-D: Diabetic; D+SFN 0.5, D+SFN 1: Diabetic group treated with sulforaphane 0.5 and 1 mg/kg respectively. ND+SFN 1: Non-diabetic group treated with sulforaphane 1 mg/kg. Results are expressed as Mean ± SEM; ### p<0.001 Vs ND; ** p<0.01 and *** p<0.001 Vs STZ-D (n= 6).  

Effect of sulforaphane on nerve functions motor nerve conduction velocity (MNCV) and nerve blood flow (NBF) in diabetic rats. Effect of sulforaphane on nerve functions, MNCV and NBF, in treated diabetic animals was measured in sciatic-posterior tibial conducting system using Power Lab 8sp system and LASER Doppler system respectively. Sulforaphane treatment resulted in a significant reversal of nerve conduction and perfusion deficits suggesting its beneficial effects in diabetic neuropathy. ND: non diabetic; STZ-D: Diabetic; D+SFN 0.5, D+SFN 1: Diabetic group treated with sulforaphane 0.5 and 1 mg/kg respectively. ND+SFN 1: Non-diabetic group treated with sulforaphane 1 mg/kg. Results are expressed as Mean ± SEM; ### p<0.001 Vs ND; ** p<0.01 and *** p<0.001 Vs STZ-D (n= 6).  

Source publication

Similar publications

Chapter
Full-text available
Diagnostic Considerations The creation of an arteriovenous hemodial-ysis access establishes a low-resistance pathway that always shunts a fraction of the arterial inflow into the low-pressure venous circulation. In addition, because of the ex-tremely low resistance and high capacitance of the venous circulation, blood flow in the artery distal to t...
Article
Full-text available
Advanced glycation end-products (AGEs) are heterogeneous molecules produced by the non-enzymatic glycation of proteins, lipids, or nucleic acids during hyperglycaemia. Accumulation of AGEs in the peripheral nerves has recently been proposed as an additional risk factor for the development of diabetic neuropathy (DN). The gold standard for measureme...
Article
Full-text available
The development and progression of diabetic polyneuropathy (DPN) are due to multiple mechanisms. The creation of reliable animal models of DPN has been challenging and this issue has not yet been solved. However, despite some recognized differences from humans, most of the current knowledge on the pathogenesis of DPN relies on results achieved usin...
Article
Full-text available
Epalerstat {systematic name: (5 Z )-5-[(2 E )-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidine-3-acetic acid} crystallized as an acetone monosolvate, C 15 H 13 NO 3 S 2 ·C 3 H 6 O. In the epalerstat molecule, the methylpropylenediene moiety is inclined to the phenyl ring and the five-membered rhodamine ring by 21.4 (4) a...
Article
Full-text available
Introduction: The objective of this study was to evaluate the prevalence of vascular complications among diabetes patients (DP), to find out the relationship with risk factors and to assess the effect of diabetic check-up (DC) in the onset of these complications. Methods: Clinical and laboratory data of DP followed between 2000 and 2009 were retros...